文献速递泌尿生殖骨肌技术与安全DR

一种改善转移性前列腺癌同位素骨扫描判读的新工具

A novel tool for improving the interpretation of isotope bone scans in metastatic prostate cancer.
PubMed 文献 · Br J Radiol · 2020-09-03

研究利用62例前列腺癌疑似骨转移患者的同位素骨扫描图像,在MATLAB中设计并实现转移性骨扫描工具(MetsBST),通过定义阈值识别转移性骨病灶的纹理和大小。MetsBST与商用自动化骨扫描指数(aBSI)结果高度一致(R²=0.9189),并能区分多模式治疗(镭-223与外照射放疗)下不同骨转移灶的治疗反应。

要点

  • MetsBST与商用aBSI定量结果高度一致,R²=0.9189。
  • MetsBST可区分不同骨转移灶对多模式治疗(镭-223和外照射放疗)的反应差异。
  • MetsBST减少主观判读导致的肿瘤负荷评估变异性,可作为核医学扫描报告的有用辅助工具。

核心结论

  • MetsBST与商用软件aBSI的结果高度一致(R²=0.9189)。
  • MetsBST通过区分不同骨转移灶对多模式治疗的反应,引入了新的临床用途。
  • MetsBST减少主观判读造成的肿瘤负荷评估变异性,是核医学扫描报告的有用辅助工具,并可能改善转移性前列腺癌的治疗决策。

研究设计与样本

  • 研究纳入62例诊断为前列腺癌并疑似骨转移的患者,使用其同位素骨扫描图像。
  • 在MATLAB中设计并实现MetsBST,通过定义阈值识别转移性骨病灶的纹理和大小。
  • 采用回归分析将MetsBST结果与商用自动化骨扫描指数(aBSI)进行比较。
  • 对接受多模式治疗(镭-223和外照射放疗)的患者进行亚区域分析,量化多个骨部位的转移病变范围。

关键影像表现/征象

  • MetsBST通过定义阈值识别转移性骨病灶的纹理和大小。
  • 亚区域分析显示MetsBST可量化接受多模式治疗(镭-223和外照射放疗)患者多个骨部位的转移病变范围,以说明不同治疗下骨转移反应的差异。

诊断标准与关键数值

  • MetsBST与aBSI的回归分析显示R²=0.9189。

临床应用与阅片要点

  • MetsBST减少主观判读导致的肿瘤负荷评估变异性,可作为核医学扫描报告的有用辅助工具。
  • MetsBST可能改善转移性前列腺癌的治疗决策。
  • MetsBST能够区分不同骨转移灶对多模式治疗(镭-223和外照射放疗)的反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The isotope bone scan (IBS) is the gold-standard imaging modality for detecting skeletal metastases as part of prostate cancer staging. However, its clinical utility for assessing skeletal metastatic burden is limited due to the need for subjective interpretation. We designed and tested a novel custom software tool, the Metastatic Bone Scan Tool (MetsBST), aimed at improving interpretation of IBSs, and compared its performance with that of an established software programme.

METHODS: We used IBS images from 62 patients diagnosed with prostate cancer and suspected bone metastases to design and implement MetsBST in MATLAB by defining thresholds used to identify the texture and size of metastatic bone lesions. The results of MetsBST were compared with those of the commercially available automated Bone Scan Index (aBSI) with regression analysis.

RESULTS: There was strong agreement between the MetsBST and aBSI results (R2 = 0.9189). In a subregional analysis, MetsBST quantified the extent of metastatic disease in multiple bone sites in patients receiving multimodality therapy (radium-223 and external beam radiotherapy) to illustrate the differences in bone metastatic response to different treatments.

CONCLUSION: The results of MetsBST and the commercial software aBSI were highly consistent. MetsBST introduces novel clinical utility by its ability to differentiate between the responses of different bone metastases to multimodality therapies.

ADVANCES IN KNOWLEDGE: MetsBST reduces the variability in assessment of tumour burden caused by subjective interpretation. Therefore, it is a useful aid to physicians reporting nuclear medicine scans, and may improve decision-making in the treatment of metastatic prostate cancer.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Alshehri AHD, Osman SOS, Prise KM, et al. A novel tool for improving the interpretation of isotope bone scans in metastatic prostate cancer. Br J Radiol. 2020. PMID: 32880475. doi:10.1259/bjr.20200775

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。